Scarica l'app Stockscreener
0.2842
1.00%
0.0028
Dopo l'orario di chiusura:
.28
-0.0042
-1.48%
Precedente Chiudi:
$0.2814
Aprire:
$0.2793
Volume 24 ore:
343.84K
Relative Volume:
0.03
Capitalizzazione di mercato:
$7.83M
Reddito:
$9.37M
Utile/perdita netta:
$-8.45M
Rapporto P/E:
-0.3509
EPS:
-0.81
Flusso di cassa netto:
$-7.27M
1 W Prestazione:
+1.50%
1M Prestazione:
+34.76%
6M Prestazione:
-72.67%
1 anno Prestazione:
-87.48%
Intervallo 1D:
$0.2698
$0.289
Intervallo di 1 settimana:
$0.26
$0.3156
Portata 52W:
$0.1639
$2.9893
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Nome
Bioaffinity Technologies Inc
Settore
Industria
Telefono
210-698-5334
Indirizzo
3300 NACOGDOCHES ROAD, SAN ANTONIO
Confronta BIAF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.2842 | 7.83M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
401.90 | 152.06B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.02 | 135.91B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
524.91 | 41.29B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.80 | 31.79B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
152.32 | 24.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Bioaffinity Technologies Inc Borsa (BIAF) Ultime notizie
BIAFbioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - mx.advfn.com
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence - mx.advfn.com
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung - Business Wire
Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Grows By 58.8% - Defense World
bioAffinity Receives Nasdaq Non-Compliance Notice - TipRanks
BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors - Insider Monkey
BioAffinity Technologies Announces New U.S. Patent For Novel Broad Spectrum Cancer Therapeutics - marketscreener.com
BIAF Gains New Patent for Innovative Cancer Treatment Method | B - GuruFocus
Revolutionary Cancer Treatment Patent: bioAffinity's New Therapy Kills Cancer Cells While Sparing Healthy Ones - Stock Titan
bioAffinity Technologies Enters Sales Agreement with WallachBeth - TipRanks
bioAffinity Technologies (NASDAQ:BIAF) Trading Down 3.1% – What’s Next? - Defense World
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline - MSN
bioAffinity Technologies names new chief medical officer By Investing.com - Investing.com South Africa
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer - citybiz
BioAffinity Technologies (BIAF) Appoints Gordon Downie as Chief Medical Officer | BIAF Stock News - GuruFocus
bioAffinity Technologies names new chief medical officer - Investing.com Australia
From Olympic Bronze to Cancer Breakthrough: bioAffinity Names Elite Physician as New CMO - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
bioAffinity Technologies Sets 2025 Annual Meeting Date - TipRanks
bioAffinity Technologies Reports Strong Q1 2025 Growth - MSN
bioAffinity Technologies, Inc. SEC 10-Q Report - TradingView
bioAffinity Technologies Reports First Quarter 2025 Results - Business Wire
bioAffinity Technologies Completes $3.2M Public Offering - TipRanks
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering - The Malaysian Reserve
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer - Stock Titan
bioAffinity announces $3.25 million securities offering By Investing.com - Investing.com Nigeria
bioAffinity Technologies completes $3.25 million offering By Investing.com - Investing.com South Africa
BioAffinity Technologies Closes $3.25 Million Offering - marketscreener.com
bioAffinity Technologies (BIAF) Completes $3.25M Securities Offering | BIAF Stock News - GuruFocus
bioAffinity Technologies completes $3.25 million offering - Investing.com
bioAffinity Technologies Announces Closing of $3.25 Million Offering - Bluefield Daily Telegraph
bioAffinity Technologies Boosts Data Acquisition for CyPath Lung Test - Medical Product Outsourcing
BioAffinity Technologies announces pricing of $3.25M offering - Yahoo Finance
Crude Oil Rises Sharply; US Trade Deficit Widens In March - Benzinga
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering - Eastern Progress
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies - NewsBreak: Local News & Alerts
Cancer Detection Biotech bioAffinity Secures Fresh $3.25M Funding: Key Details of Latest Stock Offering - Stock Titan
bioAffinity announces $3.25 million securities offering - Investing.com Australia
Dow Falls Over 250 Points; Marriott Posts Upbeat Earnings - Benzinga
bioAffinity Technologies Announces Pricing of $3.25 Million Offering - Business Wire
Top Stock Reports for Alphabet, Berkshire Hathaway & Visa - Yahoo Finance
Japanese startup ‘Craif’ raises US$22M to bring urine cancer biopsy to the U.S. - Mugglehead Magazine
bioAffinity Technologies (NASDAQ:BIAF) Shares Up 2.7% – Still a Buy? - Defense World
bioAffinity Technologies streamlines lung cancer detection test By Investing.com - Investing.com Canada
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost - BioSpace
bioAffinity Technologies streamlines lung cancer detection test - Investing.com
Bioaffinity Technologies Inc Azioni (BIAF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):